Sagimet Biosciences Inc.
SGMT
$7.11
-$0.24-3.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -100.00% | -- |
| SG&A Expenses | 8.34% | 19.98% | 23.51% | 48.13% | 128.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.75% | 88.67% | 66.32% | 49.13% | 32.46% |
| Operating Income | -84.39% | -100.20% | -77.14% | -59.53% | -25.54% |
| Income Before Tax | -103.01% | -104.58% | -63.46% | -39.36% | -4.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -103.01% | -104.58% | -63.46% | -39.36% | -4.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.01% | -104.58% | -63.46% | -39.36% | -4.34% |
| EBIT | -84.39% | -100.20% | -77.14% | -59.53% | -25.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -56.44% | 95.16% | 98.00% | 98.84% | 99.22% |
| Normalized Basic EPS | -56.43% | 95.16% | 98.00% | 98.84% | 99.22% |
| EPS Diluted | -56.44% | 95.16% | 98.00% | 98.84% | 99.22% |
| Normalized Diluted EPS | -56.43% | 95.16% | 98.00% | 98.84% | 99.22% |
| Average Basic Shares Outstanding | 25.47% | 81.24% | 198.20% | 521.45% | 13,691.46% |
| Average Diluted Shares Outstanding | 25.47% | 81.24% | 198.20% | 521.45% | 13,691.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |